Led · Debt Financing · Feb 2026

Founded in 2014, OSSIO aims to transform orthopedic surgery by replacing traditional metal implants with its proprietary OSSIOfiber Intelligent Bone Regeneration Technology. The company’s bio-integrative implants are designed to provide strong fixation while naturally integrating with bone, eliminating the need for hardware removal and improving patient outcomes. Product development and manufacturing are conducted in Caesarea, Israel, while commercial operations are headquartered in Palmetto, Florida. Management plans to use additional growth capital to accelerate global expansion of the technology across the multibillion-dollar orthopedic fixation market. OSSIO positions itself as a disruptive alternative for patients, physicians, providers and payors seeking better clinical and economic value. Although no revenue or user metrics were disclosed, the firm emphasizes rapid commercialization and international scaling. The recent financing partnership underscores OSSIO’s focus on maintaining its mission while gaining the resources required for broader market penetration.

Led · Debt Financing · Feb 2024

Vero Biotech develops Genosyl, an FDA-approved portable, tankless system that delivers a constant concentration of inhaled nitric oxide for cardiac patients in acute settings, targeting persistent pulmonary hypertension in newborns. The device is intended to eliminate the need for large nitric oxide tanks in neonatal intensive care units, which are costly and labor-intensive. Vero says it is currently generating revenue and has raised nearly $300 million to date. Company leadership reports a rapid uptake in demand for Genosyl and is focused on ramping commercial deployment. Management plans to use new funding to support continued commercial expansion, increase device-building spend, and advance other R&D initiatives. Board director Todd Brady indicated the financing will enable faster market deployment. Vero Biotech is a commercial-stage healthcare company focused on neonatal intensive care and the acute care hospital community. Its core product is the GENOSYL Delivery System (DS), a tankless, portable inhaled nitric oxide (iNO) delivery system engineered with redundant backup features, an easy-to-use interface, and portability. The third generation of the GENOSYL DS was recently approved by the FDA. The company intends to use the proceeds from its recent financing to support further development and commercialization of GENOSYL DS. Vero Biotech raised $30M in funding in a round led by Petrichor, and Petrichor partner Patrick Lally has joined the company's board. The company is led by CEO and President Brent V. Furse and is based in Atlanta, GA. Vero Biotech LLC is an Atlanta, Georgia–based biotechnology company focused on the design, development and commercialization of next‑generation products for patients with pulmonary and cardiac diseases. Led by CEO Brent V. Furse, the company developed the GENOSYL Delivery System (GENOSYL DS), an inhaled nitric oxide delivery system that is approved by the U.S. FDA. The GENOSYL DS delivers nitric oxide, a vasodilator used in care of patients with adult respiratory distress syndrome and persistent pulmonary hypertension of the neonate. The system was authorized by the FDA for expanded emergency use for patients with cardiopulmonary complications associated with COVID‑19, was granted an emergency IND for at‑home use, and is approved for interhospital transport in ground, fixed‑wing and rotary‑wing environments. The company closed a $50M senior secured term loan from Runway Growth Capital, providing additional financing. Vero Biotech was formerly known as GeNO LLC.

Led · Equity · Mar 2023

Amelia provides a platform that captures rapid innovation across AI ecosystems and converts those advances into enterprise-grade products. Enterprises use Amelia to drive revenue through conversational experiences and to increase productivity via operations automation. The company is consistently recognized by analyst firms as a market leader. Amelia is NYC-based and focuses on delivering Trusted AI solutions for large customers. Following a new $175M investment, leadership changes will reposition operational oversight and deepen executive involvement in growth. Founder Chetan Dube will concentrate on research and development and technical delivery.

Led · Equity · Feb 2023

Vytalize Health is a Hoboken, NJ–based risk-bearing care provider enablement platform led by CEO Faris Ghawi. It partners with primary care practices for more than 250,000 patients and delivers evidence-based recommendations at the point of care. The platform provides the right data at the right time in the clinical workflow to physicians and their staff to make practices more efficient and effective. Vytalize also offers financial incentives to practices that follow recommendations and drive better health outcomes. The company intends to use the new funding to accelerate its goal of advancing responsible value-based care for seniors by strengthening primary care practices. Vytalize Health offers an all-in-one, vertically integrated value-based care solution that combines a risk-bearing entity, a virtual and in-home clinic, and a broad technology platform. The company partners with independent primary care practices to enable data-driven, holistic care and last-mile patient engagement. Vytalize supports roughly 130,000 senior patients through 280 primary care practices across 16 states and is responsible for $2 billion in medical spending. The business has grown its patient base 150% year-over-year and has begun contracting with regional and national Medicare Advantage plans and commercial plans. Last year the company acquired patient communication company MedPilot and is integrating additional downstream network partners, including hospitals, specialty networks, ancillary providers, and digital health companies. Management plans to use additional capital to continue investing in care delivery infrastructure, expand into new markets, and grow the team.

Led · Debt Financing · Aug 2022

Yieldstreet operates a technology-driven private markets investment platform offering access to alternative assets across ten asset classes, including real estate, private credit, private equity, and art. The company reports having over 500,000 members using its platform. Yieldstreet closed an initial $45 million equity investment as part of a planned $60 million Series D to fund growth and continue delivering private market alternatives. Management says the new capital will be used to accelerate growth plans and enhance the company’s technological infrastructure. Investors and partners highlighted Yieldstreet’s distribution and platform capabilities as core strengths. The financing is described as strengthening Yieldstreet’s financial footing as it expands private markets opportunities for investors. Yieldstreet operates an online marketplace that lets eligible retail investors access private-market alternatives such as real estate, private credit, private equity, art and other asset classes. The company creates funds and products with lower minimums to widen access to investment strategies that were previously mostly available to institutions and ultra-wealthy individuals. Yieldstreet emphasizes partnerships with asset managers, sponsors, and originators to source diversified opportunities across litigation finance, small business, consumer, private funds and real estate. Founded in 2015 and headquartered in New York City, Yieldstreet has attracted more than 400,000 users and over $3 billion in funding on its platform to date. The company positions itself to scale its product suite and increase the number and scope of offerings for its investor base. Management says additional capital and financing capacity will accelerate deal flow and platform growth. Yieldstreet is a multi-asset alternative investment platform that gives retail investors access to alternative investments previously reserved for institutions and ultra-high-net-worth individuals. Its technology platform offers products across asset classes including Real Estate, Commercial, Consumer, Art, Marine, Legal Finance and Aviation. Since its foundation in 2015, Yieldstreet has funded over $2.5 billion of investments and has over 325,000 members on its platform. The company is headquartered in New York City and has offices in Brazil, Greece and Malta. Yieldstreet plans to use new capital to advance its technology roadmap, expand sales and marketing capabilities, and grow its international distribution. Its stated mission is to help millions generate $3 billion of income outside the traditional public markets by 2025, and it is backed by venture capital firms, large family offices and private equity investors. Yieldstreet operates an online marketplace that fractionalizes institutional-style, asset-backed investments (real estate, art, marine/shipping, legal finance, commercial loans) for retail investors. The company has funded nearly $1.9 billion on its platform and reports about 300,000 consumers signed up, up from roughly 100,000 in February 2019. Since inception it says it has provided nearly more than $950 million in principal and interest payments to investors. Yieldstreet expects over 50% revenue growth in the current year versus 2020. The firm plans to use new capital to expand its user base, develop new investment products, pursue strategic acquisitions and explore international expansion into Europe and Asia. Yieldstreet was co‑founded by Milind Mehere and Michael Weisz and maintains headquarters in New York City with offices in Brazil, Greece and Malta. YieldStreet operates an online platform that offers access to alternative investments across asset classes including real estate, marine/shipping, legal finance and commercial loans. The company has attracted more than $600 million invested on its platform from over 100,000 members, with an expected 12% IRR and more than $300 million in principal and interest paid to investors. Until now the platform has required users to be accredited investors; YieldStreet also offers YieldStreet Wallet, a savings product paying 2.2% interest that is open to everyone. The new capital will be used to expand the platform and create investment vehicles that do not require accredited status, and the company is working through the legal and regulatory aspects of those products. Management is also exploring ways to enable retirement and IRA account access for users. YieldStreet operates in the U.S. and positions itself as a democratising force to broaden access to products previously reserved for institutions.